Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad to Participate in Upcoming September 2019 Conferences

Celyad to Participate in Upcoming September 2019 Conferences